Sign or Symptom
Pharmaceutical CEOs Emphasize Transparency to Counter Anti-Vaccine Sentiment in the US
Anti-vaccine movement, Transparency, GSK, Sanofi, Vaccine hesitancy, Public health
Elinzanetant Shows Promise in Reducing Hot Flashes in Women Undergoing Breast Cancer Therapy
Elinzanetant, Vasomotor Symptoms, Breast Cancer, Adjuvant Endocrine Therapy, Hot Flashes, Non-Hormonal Treatment
Acadia Pharmaceuticals Secures Exclusive Licensing Deal for Saniona’s Tremor Treatment Asset Worth Up to $582 Million
Acadia Pharmaceuticals, Saniona, tremor treatment, licensing deal, biobucks, neurological disorder
GSK Advances Regulatory Filings for Linerixibat Following Successful Phase 3 Trial in PBC Itch Treatment
GSK, Linerixibat, PBC Itch, Phase 3 Trial, Regulatory Filings, Cholestatic Pruritus
Roche and Flare Therapeutics Launch $1.8B-Plus Cancer Collaboration Targeting Transcription Factors
Roche, Flare Therapeutics, transcription factors, cancer drugs, oncology, biotech collaboration
Tezspire Shows Promise in Treating Chronic Rhinosinusitis with Nasal Polyps
Tezspire, chronic rhinosinusitis with nasal polyps (CRSwNP), AstraZeneca, Amgen, WAYPOINT trial, TSLP inhibitor, nasal congestion, nasal polyps.
Vertex Unveils Promising Data on Non-Opioid Painkiller Suzetrigine Ahead of FDA Decision
Suzetrigine, non-opioid painkiller, acute pain, FDA approval, Vertex Pharmaceuticals, NaV1.8 inhibitor, pain management
Vertex’s Non-Opioid Pain Drug Suzetrigine Nears FDA Approval: A Breakthrough in Acute Pain Management
Suzetrigine, Non-opioid pain drug, Acute pain management, FDA approval, Vertex Pharmaceuticals, NaV1.8 pain signal inhibitor, Opioid epidemic, Pain relief without addiction risk
Vertex’s Non-Opioid Pain Drug, Suzetrigine (VX-548), Shows Promising Results in Phase III Trials, Aiming for FDA Approval
Non-opioid pain drug, Suzetrigine (VX-548), Vertex Pharmaceuticals, Phase III trials, acute pain, FDA approval, opioid alternative
FDA Approves Avadel’s Lumryz for Pediatric Narcolepsy Patients
Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)